Assuntos
Antibacterianos/uso terapêutico , Cefalosporinas/uso terapêutico , Cefradina/uso terapêutico , Infecções/tratamento farmacológico , Tobramicina/uso terapêutico , Queimaduras/tratamento farmacológico , Resistência Microbiana a Medicamentos , Quimioterapia Combinada , Serviços Médicos de Emergência , Fraturas Expostas/tratamento farmacológico , Humanos , Osteomielite/tratamento farmacológico , Pneumonia/tratamento farmacológico , Infecção da Ferida Cirúrgica/tratamento farmacológico , Infecções Urinárias/tratamento farmacológicoRESUMO
Cephalosporins are being given more and more frequently empirically as initial therapy, until the bacteriological findings become available. The wide selection of cephalosporins available make the choice of the most suitable one difficult for the clinician. Cephazolin, cephradine and cephacetrile were tested against three standard bacteria strains (Escherichia coli, Staphylococcus aureus, Kelebsiella pneumoniae) in normal broth and with the addition of 30% inactivated human serum; the geometric mean of the minimum inhibitory concentration (MIC) was determined by serial dilution, and the minimum bactericidal concentration (MBC) by inoculation onto solid medium. On the addition of 30% serum, cephazolin showed a reduction in effectivity of up to 360% for the MIC and up to 74% for the MBC, cephacetril up to 250% for the MIC and 100% for the MBC, and cephradin a maximum loss of 16%. Successful treatment of a severe infection requires a high drug level or a corresponding tissue titer. Due to the high tissue concentration of cephradin and the unrivalled stable antibacterial effectivity in serum, this antibiotic can be recommended for clinical use.
Assuntos
Atividade Bactericida do Sangue , Cefalosporinas/farmacologia , Escherichia coli/efeitos dos fármacos , Klebsiella pneumoniae/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacos , Cefazolina/farmacologia , Cefacetrila/farmacologia , Cefradina/farmacologia , Humanos , Testes de Sensibilidade MicrobianaRESUMO
Naftidrofuryl hydrogen oxalate was used for 4 1/2 years in 216 patients with chronic arterial occlusive disease in a surgical clinic. An increase of 1 to 10 times the walking distance could be obtained in over 77% of cases in Fontaine's stage II by a genuine combination treatment with active vascular muscle training and continuous intravenous drip lasting for an average of 28 days. The continuous drip treatment was made possible by a specially designed infusion rucksack 19% of the cases still showed a moderate effect on the walking capacity. By elimination of pain at rest and healing of trophic disorders, it was possible to transfer over 68% of the patients in Stages III and IV to Stage II.